TG Therapeutics Inc (STU:NKB2)
€ 14.742 -0.034 (-0.23%) Market Cap: 2.35 Bil Enterprise Value: 2.26 Bil PE Ratio: 75.14 PB Ratio: 15.96 GF Score: 72/100

TG Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 04:00PM GMT
Release Date Price: €11.99 (-4.23%)
Ankit Agarwal;JPMorgan;Analyst

Good morning, everyone. My name is Ankit Agarwal. I'm an associate with the investment banking group here at JPMorgan. It's my pleasure to introduce our next speaker, Mr. Michael Weiss, CEO of TG Therapeutics.

Michael S. Weiss
TG Therapeutics, Inc. - Executive Chairman, CEO & President

Great. Thank you so much for that lovely introduction. Thanks, JPMorgan for having us again, Thursday morning. It's our favorite slot. And thanks, everyone, who got up early on Thursday morning to join us.

So let me just get going here. Let's see if I got this. I've received very clear instructions on how to use this machine.

So before I get started, let me just mention, I will be making some forward-looking statements. For those of you who are interested, I do encourage you to look at our public disclosure documents available on the Internet, worldwide web.

So just by the way of background, we founded the company about 8 years ago with one goal in mind: to create the best possible

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot